Compositions for use as a prophylactic agent to those at risk of infection of tuberculosis, or as secondary agents for treating infected tuberculosis patients
US-2024382575-A1 · Nov 21, 2024 · US
Mycobacterium tuberculosis ΔESX-3 mutants
US9637749B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9637749-B2 |
| Application number | US-201314399557-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 10, 2013 |
| Priority date | May 10, 2012 |
| Publication date | May 2, 2017 |
| Grant date | May 2, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.
First claim
Opening claim text (preview).
What is claimed: 1. A method of eliciting an immune response in a subject comprising administering to the subject a composition comprising a non-naturally occurring mutant Mycobacterium tuberculosis bacterium, wherein the mutation of the mutant M. tuberculosis consists of a deletion of the entire esx-3 region of a genome thereof, in an amount effective to elicit an immune response. 2. The method of claim 1 , wherein the mutant M. tuberculosis is administered as a composition comprising the mutant Mycobacterium tuberculosis bacterium and a carrier. 3. The method of claim 2 , wherein the carrier is a pharmaceutically acceptable carrier. 4. The method of claim 2 , wherein the composition further comprises an immunological adjuvant. 5. The method of claim 1 , wherein the mutant Mycobacterium tuberculosis bacterium is live.
Assignees
Inventors
Classifications
avirulent or attenuated · CPC title
- A61K39/04Primary
Mycobacterium, e.g. Mycobacterium tuberculosis · CPC title
- C12N15/74Primary
Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora · CPC title
Chemistry & Metallurgy · mapped topic
Mycobacterium smegmatis · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9637749B2 cover?
- Isolated mutant Mycobacterium tuberculosis bacteria comprising a deletion in the ESAT-6 gene cluster region 3 (esx-3 region) are provided, as well as compositions comprising such, methods of production thereof and methods of use thereof.
- Who is the assignee on this patent?
- Albert Einstein College Medicine Yeshiva Univ, Albert Einstein College Medicine Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/04. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue May 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).